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Regular Article
TRANSPLANTATION
Megakaryocytes promote murine osteoblastic HSC niche expansion and
stem cell engraftment after radioablative conditioning
Timothy S. Olson,1,2 Anna Caselli,3 Satoru Otsuru,1 Ted J. Hofmann,1 Richard Williams,4 Paolo Paolucci,3
Massimo Dominici,3 and Edwin M. Horwitz1
1Division of Oncology and 2Division of Hematology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA; 3Department of Medical
and Surgical Sciences of Children & Adults, University Hospital of Modena and Reggio Emilia, Modena, Italy; and 4Department of Oncology, St. Jude
Children’s Research Hospital, Memphis, TN
Key Points
• After radioablative conditioning,
host megakaryocytes
promote endosteal HSCniche
expansion and donor stem
cell engraftment.
• Thrombopoietin administration
before radiation and bone
marrow transplant enhances
megakaryocyte promotion of
HSC engraftment.
Successful hematopoietic stem cell (HSC) transplantation requires donor HSC engraft-
ment within specialized bone marrow microenvironments known as HSC niches. We have
previously reported a profound remodeling of the endosteal osteoblastic HSC niche after
total body irradiation (TBI), defined as relocalization of surviving megakaryocytes to the
niche site andmarked expansion of endosteal osteoblasts. We now demonstrate that host
megakaryocytes function critically in expansion of the endosteal niche after preparative
radioablation and in the engraftment of donor HSC. We show that TBI-induced migration of
megakaryocytes to the endosteal niche depends on thrombopoietin signaling through the
c-MPL receptor on megakaryocytes, as well as CD41 integrin-mediated adhesion. Moreover,
niche osteoblast proliferation post-TBI required megakaryocyte-secreted platelet-derived
growth factor-BB. Furthermore, blockade of c-MPL–dependent megakaryocyte migration
and function after TBI resulted in a significant decrease in donor HSC engraftment in
primary and competitive secondary transplantation assays. Finally, we administered
thrombopoietin to mice beginning 5 days before marrow radioablation and ending 24
hours before transplant to enhance megakaryocyte function post-TBI, and found that this strategy significantly enhanced donor
HSC engraftment, providing a rationale for improving hematopoietic recovery and perhaps overall outcome after clinical HSC
transplantation. (Blood. 2013;121(26):5238-5249)
Introduction
Inadequate donor hematopoietic stem cell (HSC) engraftment is a
major cause of morbidity after clinical stem cell transplantation
(SCT).1 Although considerable research has focused on improving
donor engraftment through reﬁnement of the HSC graft itself,2
therapeutic strategies to enhance receptivity of the recipient’s bone
marrow (BM) microenvironment are only beginning to be explored.3
HSCs preferentially engraft in specialized areas of BM known
as HSC niches.4 After marrow radioablation with total body irradiation
(TBI), a critical site of donor HSC engraftment is the endosteal
HSC niche,5,6 located at the interface between metaphyseal
trabecular bone and BM and consisting of osteoblasts, mesenchymal
stromal cells, and specialized hematopoietic elements.7,8 Recently,
we reported that endosteal niche osteoblasts undergo marked
expansion after TBI to form 3 or more activated layers at the
endosteal surface.9 Moreover, we discovered that TBI induces marked
relocalization of megakaryocytes from the central BM space to the
endosteal surface proximal to this niche osteoblast expansion.9
Although not previously described as endosteal niche elements,
megakaryocytes are known regulators of osteoblast proliferation
and differentiation.10-13 Through expression of c-MPL and
CXCR4,14,15 megakaryocytes and HSC subpopulations share
responsiveness to thrombopoietin (TPO) and stromal-derived factor
(SDF)-1, both expressed by niche cells.16 Furthermore, megakar-
yocytes produce mediators that directly inﬂuence homeostatic and
postinjury HSC/progenitor function.17,18 Whether megakaryocytes,
which survive for several days after TBI,19 can use these shared
pathways to exert effects on the host niche post-TBI, thereby
inﬂuencing donor HSC engraftment posttransplant, is unclear.
Here, we show that host megakaryocytes facilitate post-TBI niche
osteoblast expansion and are required for efﬁcient donor HSC
engraftment after SCT. We then demonstrate that enhancement of
host megakaryocyte function before TBI promotes donor HSC
engraftment and provides an effective strategy to enhance HSC
engraftment after clinical transplantation.
Materials and methods
Mice and irradiation
Mouse colonies were maintained under speciﬁc pathogen-free conditions.
Experiments were conducted according to protocols approved by the
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Institutional Animal Care and Use Committee at The Children’s Hospital of
Philadelphia. Wild-type (WT) C57BL/6 mice were obtained from Jackson
Laboratories. Homozygous c-MPL–deﬁcient (mpl2/2) mice on a C57BL/6
background were obtained from Genentech. H2K-green ﬂuorescent protein
(GFP) mice20 on a C57BL6 background were obtained from institutional
colonies. Mice were 6 to 12 weeks old at the start of experiments.
TBI was performed with either a 137Cs source (Mark II irradiator;
J.L. Sheppard and Associates) or (because of facility change) a radiograph
source (X-RAD 320: Precision X-ray Inc). Radiation for osteoblast expansion
and short-term (ST) primary transplantation studies was given as a
single 1125 cGy dose. Secondary recipients in competitive secondary trans-
plantation assays received 1000 to 1125 cGy in 2 split doses to decrease late
nonhematologic toxicity.
Reagents and in vivo treatments
Puriﬁed blocking anti-CD41 (MWREG30) antibody (BD Biosciences) was
injected (5 mg) intraperitoneally at the time of TBI and at 24 hours later.
CXCR4 inhibitor AMD3100 (Sigma) was injected subcutaneously at 5 mg/kg
every 12 hours post-TBI. Blocking anti-c-MPL antibody (AMM2) (generous
gift of Kyowa Hakko Kirin Co.), was injected intraperitoneally (1 mg/kg) at
the time of TBI. Imatinib (LC Labs) was given by gavage (300 mg/kg/dose)
every12hoursbeginning thedaybeforeTBI.BrdU(BDBiosciences)was injected
intraperitoneally (75 mg/kg/dose) at 24 and 42 hours post-TBI. Recombinant
PDGF-BB (Peprotech) was administered at 0.5 mg/kg/dose intravenously every
12 hours post-TBI. Recombinant mouse TPO (Peprotech) was administered
intraperitoneally daily at low (10 mg/kg) or high (50 mg/kg) doses.
Histology studies
Mouse femora and tibiae were ﬁxed in 10% formalin. Bones were decalciﬁed
before dehydration, parafﬁn-embedded, and cut into 5- to 6-mm sections. For
osteoblast proliferation analysis, sections were stained with Harris hematoxylin
and eosin (Sigma-Aldrich) and were examined with 633/1.4NA oil, 203/
0.5NA dry, and 403/0.75NA dry objectives (Zeiss AxioImager 200M; Carl
Zeiss). Photomicrographs were acquired using an Axiocam HRc camera and
AxioVision 4.5SP1 software (Carl Zeiss). Individual high-power ﬁelds (HPFs)
(203) of metaphyseal bone were numerically scored in a blinded fashion from
0 to 4, representing the predominant number of contiguous endosteal cell layers.
Scores for 3 to 5 HPFs per section encompassing 2 to 5 sections per mouse
were averaged to generate a composite score per mouse (n>5 mice per group).
Megakaryocyte immunostaining was performed with polyclonal goat
anti-mouse CD41 (1:50 dilution) (Santa Cruz Biotechnologies), biotinylated
rabbit anti-goat secondary antibody, avidin-biotin complexes, and Novared
peroxidase substrate (Vector Laboratories). Immunostained sections of
metaphyseal BM were analyzed per HPF (203) for megakaryocyte total
number and location, either at the endosteal surface (within 1 cell diameter)
or within the inner marrow space. At least 4 HPF per section and>2 sections
per mouse were averaged (n >4 mice per group). Immunostaining for BrdU
incorporation was performed with anti-BrdU-POD FAB fragments (Roche)
per manufacturer protocol. Terminal deoxynucleotidyltransferase-mediated
dUTP nick end labeling (TUNEL) assays were performed with a TACS 2
TdT-DAB in situ apoptosis detection kit and a TACS-Nuclease positive
control (Trevigen, Inc.) per the manufacturer’s instructions.
Megakaryocyte and osteoblast coculture
Primary WT megakaryocytes and osteoblasts were isolated according to
previously published methods.9,21 For coculture experiments, osteoblasts
were plated onto 6-well plates (50 000 cells per well). Two days later, 1 plate
was trypsinized and counted (TC10 system [BIO-RAD] or hemocytometer)
to provide starting osteoblast concentration. Megakaryocytes were then
plated into wells (25 000-30 000 per well) either directly onto osteoblasts
or across a 0.4 mm Falcon insert (BD Biosciences). Speciﬁed cultures were
treated with 5 mM of imatinib (LC Labs), 2.5 mg/mL of anti-CD41
(MWREG30), 2.5 mg/mL of anti-c-MPL (AMM2), or 2 to 10 ng/mL of
recombinant PDGF-BB (Peprotech). Cocultures were incubated (37°C) for
5 days in media supplemented with 50 ng/mL of TPO. Cell growth was
assessed by removing nonadherent cells, trypsinizing adherent cells, and
counting cell numbers in both fractions, adjusting for percentages of
CD411CD451 megakaryocytes and CD412CD452 osteoblasts, deter-
mined by ﬂow cytometry analysis.
Primary and secondary transplantation assays
Irradiated (1125 cGy) primary recipient WT or mpl2/2 mice 6 anti-CD41 or
TPO treatment received 53 106 whole BM cells from H2K-GFP donor mice
via a tail vein injection. In primary transplant analyses, BM was collected
24 hours, 3 to 7 days, and 3 weeks post-BM transplantation (BMT). After
red blood cell (RBC) lysis, BM cells were counted, stained with propidium
iodide, and assessed for live GFP1 cell percentage. Absolute GFP1 cells
were calculated as GFP1 percentage 3 total BM cell count.
For secondary transplant studies, irradiated WT or mpl2/2 primary
recipients, 6 anti-CD41 or TPO treatment, again received 5 3 106 GFP1
H2K-GFP whole BM cells at 48 hours post-TBI. At 24 to 36 hours or
3 weeks post-BMT, primary recipient BM from the bilateral femora and tibiae
was collected. On the basis of an established metric,22 all BM collected from
a single primary recipient was deﬁned as a 25% BM equivalent (BME) dose.
BM was pooled from >4 primary recipient mice per group, and a 5% or
6.25% BME dose (one ﬁfth and one fourth of all marrow collected from
a single primary recipient, respectively) was injected into irradiated WT
secondary recipient mice along with 105 or 23 105 unirradiated WT whole
BM cells. Secondary recipients were assessed at 3 to 28 weeks after secondary
BMT for percentages of peripheral blood RBCs; platelets; CD31 T cells;
B2201 B cells; and GR-11 myeloid cells expressing GFP, which directly
deﬁnes relative engraftment efﬁciency mediated by the niche in distinct
primary treatment groups.
Flow cytometric measurements and enzyme-linked
immunosorbent assay (ELISA)
Flow cytometry analysis was performed on BD FACSCalbur and BD
FACSAria cytometers using the following antibodies (BD Biosciences):
anti-mouse CD3 (154-2C11), B220 (RA3-6B2), GR-1 (RB6-8C5), CD41
(MWREG30), CD45 (30-F11), c-Kit (ACK2), SCA-1 (LY-6A/E), CD135
(A2F10), and CD127 (SB/199). Lineage (lin) staining included anti-mouse
TER119, GR-1, B220, CD4 (RM4-5), CD8 (53-6.7), and CD11b (M1/70).
Data were analyzed using FlowJo version 7.6.5 (Tree Star, Inc.).
To detect growth factor expression, BM cells were vigorously ﬂushed
from mouse tibiae and femora (n 5 5 mice per group) and resuspended in
500 mL of phosphate-buffered saline containing 1% Nonidet-P40 (United
States Biological) and protease inhibitor (Roche). Samples underwent 3
freeze-thaw cycles followed by centrifugation at 12 000 3 g for 5 minutes
and supernatant removal. ELISA was performed (samples run in duplicate)
for IGF-1 (50 mL/assay), PDGF-BB (50 mL), vascular endothelial growth
factor (VEGF) (50 mL), SDF-1 (20 mL), and TPO (30 mL) per the manu-
facturer’s instructions (R&D systems). For pre- vs post-TBI comparisons,
samples were normalized to the total BM cell number. For cell culture
expression analysis, ELISA was performed on undiluted supernatants, with
each independent culture (n 5 3 cultures per group) run in duplicate.
Statistical analysis
Data were analyzed for statistical signiﬁcance with the Student 2-tailed t test
(Excel 2007, Microsoft Corporation) for 2-group comparisons. For multiple
comparisons, nonparametric data, or binary comparisons, 1-way analysis of
variance (ANOVA) (with Student-Newman-Keuls or Dunnett posttest analyses
where appropriate), the Wilcoxon rank-sum test, and the Fisher exact test,
respectively, were performed using Graphpad Instat v3.1 (GraphPad Software,
www.graphpad.com).
Results
TBI induces active migration of megakaryocytes to the
endosteal niche
At 48 hours post-TBI (1125 cGy), many megakaryocytes in WT
mice relocate from the central marrow space to the endosteal
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surface (Figure 1A). At baseline, only 14% of marrow megakar-
yocytes resided proximal to the endosteum, compared with 43%
post-TBI (Figure 1B; P, .01). To determine whether megakaryocyte
relocation results from active migration or selective survival, we
administered BrdU to mice at 24 and 42 hours post-TBI, observing
BrdU incorporation in CD411 megakaryocytes at 48 hours post-
TBI (Figure 1C). TUNEL assays demonstrated no apoptotic cells
with the morphologic appearance of megakaryocytes 48 hours
post-TBI (Figure 1D). Additionally, on histology measurements,
the total BM megakaryocyte numbers in WT mice were not sig-
niﬁcantly reduced by TBI (Figure 1E; P 5 .08). Furthermore, the
percentage of megakaryocytes as a fraction of the total live BM
cells increased by 10-fold vs baseline in 48-hour post-TBI mice,
demonstrating prolonged survival of megakaryocytes relative to
other BM cell populations (supplemental Figure 1A-B). Together,
these ﬁndings indicate that megakaryocyte localization to the
endosteal niche post-TBI reﬂects dynamic migration of viable,
metabolically active cells.
c-MPL–deﬁcient (mpl2/2) mice lacked TPO responsiveness and
showed a 63% reduction in baseline BM megakaryocyte number
relative to WT mice (Figure 1E), consistent with published
ﬁndings.23,24 At 48 hours post-TBI, mpl2/2 mice had a 65%
Figure 1. Megakaryocyte migration to the endosteal niche is induced by TBI and inhibited by c-MPL deficiency and CD41 blockade. (A) Immunostaining of
metaphyseal bone (BO) and BM sections (203) for CD41-expressing (red) megakaryocytes (black arrowheads) from WT (left column) and mpl2/2 mice (right column) at
baseline (top) and at 48 hours post-TBI in the presence (bottom) or absence (middle) of CD41 blockade. (B) Percentage of endosteal megakaryocytes (mean 6 SEM) at
baseline (no TBI) or 48 hours after TBI in WT and mpl2/2 mice receiving TBI only, anti-c-MPL–blocking antibody (MPL), CXCR4 blockade with AMD3100 (CXCR4), or
anti-CD41–blocking antibody (CD41) (n $4 mice per group). *P , .05 vs unirradiated group within same strain, 1P , .01 vs WT mice receiving TBI only in other TBI-
treated groups, ‡P , .05 vs mpl2/2 mice receiving TBI only in groups with specific receptor blockade (comparisons performed by 1-way ANOVA and Dunnett posttest
analysis). (C) Immunostaining (203) for BrdU incorporation (black) in CD41-expressing (red) megakaryocytes (arrowheads) in WT vs mpl2/2 BM 48 hours after TBI. (D)
At 48 hours post-TBI in WT BM (left), few BM cells remain, and none with the morphologic appearance of megakaryocytes display TUNEL1 (brown stain, black arrow)
apoptosis, compared with a ligase-treated positive control serial section (right), with megakaryocytes (arrowheads) present in each section (203). (E) Total mega-
karyocyte number per HPF (203) in the same groups as in (B). 1P , .01 vs baseline WT or WT TBI-only group (comparisons performed by 1-way ANOVA and Dunnett
posttest analysis).
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reduction compared with WT mice, speciﬁcally in the percentage
of megakaryocytes migrating to the endosteum (P , .01; Figure 1B).
To determine whether this deﬁcit reﬂected developmental abnor-
malities in mpl2/2 megakaryocytes or, speciﬁcally, lack of TPO
responsiveness, we treated WT mice after TBI with AMM2, a
c-MPL–blocking antibody. AMM2 treatment did not decrease total
megakaryocyte numbers post-TBI, (Figure 1E) but was associated
with a 42% reduction in megakaryocyte endosteal migration
(Figure 1B; P , .01 relative to WT), indicating a key role for
TPO/c-MPL signaling in this pathway.
Functional blockade of megakaryocyte-expressed CXCR414 or
aIIbb3 integrin
25 in WT mice with AMD3100 or anti-CD41 (aIIb
subunit)–blocking antibody (MWREG30), respectively, also signif-
icantly reduced (P , .01, each comparison) megakaryocyte endosteal
migration post-TBI (Figure 1A-B). Deﬁciency of c-MPL combined
with CD41 blockade, but not with CXCR4 blockade, synergistically
reduced endosteal megakaryocytes to baseline pre-TBI percentages
(Figure 1B).
TPO-dependent megakaryocyte signaling is required for
TBI-induced osteoblast expansion
In WT mice, TBI induced not only endosteal osteoblast expansion
from a single layer at baseline to 3 to 4 layers, but also induced
morphologic changes in individual osteoblasts from ﬂattened to
a cuboidal morphologic pattern (Figure 2A), which may increase
adhesive interactions between the niche and HSC.26 Megakar-
yocytes appeared to migrate speciﬁcally to sites of this endosteal
osteoblast expansion (supplemental Figure 1C). Using a transgenic
mouse model, we conﬁrmed that the majority of this endosteal
cell expansion is composed of mature osteoblasts (supplemental
Figure 1D). In contrast, TBI-induced osteoblast expansion in mpl2/2
mice was signiﬁcantly diminished, with the endosteal surface lined
by only 1 to 2 layers, and individual osteoblasts displaying baseline
ﬂattened morphologic features (Figure 2A). By quantitative scoring
methods,9 TBI-induced endosteal osteoblast expansion was reduced
by 70% in mpl2/2 vs WT mice (Figure 2B; P , .001).
Next, we examined osteoblast expansion in WT mice treated with
AMM2 antibody to induce c-MPL blockade at the time of TBI,
thereby excluding developmental effects of c-MPL deﬁciency, in-
cluding decreased megakaryocyte numbers. This strategy resulted
in decreased post-TBI osteoblast expansion compared with that in
untreated WT mice (44% reduction; P, .001), although osteoblast
expansion (1.9-fold; P , .001) exceeded that in post-TBI mpl2/2
mice (Figure 2B). These ﬁndings suggest that both megakaryocyte
c-MPL signaling and normal megakaryocyte numbers are necessary
for maximal post-TBI endosteal niche remodeling, although we
cannot exclude whether incomplete c-MPL blockade by AMM2
was responsible for the smaller decrease in osteoblast expansion
produced by AMM2 treatment vs c-MPL deﬁciency.
CXCR4 antagonism in WT mice post-TBI led to a small but
signiﬁcant reduction (21%; P , .05) in osteoblast expansion
(Figure 2B). Anti-CD41 treatment of WT or mpl2/2 mice had no
effect on post-TBI osteoblast expansion despite severely reducing
megakaryocyte migration (Figure 2A-B). This ﬁnding led us to
hypothesize that megakaryocyte-derived paracrine mediators de-
pendent on c-MPL signaling, but not direct CD41 integrin-mediated
megakaryocyte adhesion to the niche, may promote endosteal osteo-
blast expansion post-TBI.
PDGF-BB mediates megakaryocyte effects on osteoblast
proliferation
To identify candidate paracrine mediators of TBI-induced endosteal
osteoblast expansion, we examined BM osteoblast growth factor
production at baseline vs 48 hours post-TBI, ﬁnding notable post-
TBI increases in PDGF-BB (4.9-fold; P, .001), insulin-like growth
factor (IGF)-1 (6.4-fold; P , .001), and VEGF (1.6-fold; P , .02)
Figure 2. Blockade of TBI-induced c-MPL–dependent megakaryocyte endosteal migration abrogates niche osteoblast expansion post-TBI. (A) H&E sections (633)
of WT (left panels) and mpl2/2 (right panels) metaphyseal bone (BO) and BM at baseline (top) and 48 hours post-TBI in the presence (bottom) or absence (middle) of CD41
blockade, demonstrating a single layer of endosteal osteoblasts at baseline followed by proliferation and expansion of endosteal osteoblasts in WT BM 48 hours post-TBI that
is markedly attenuated by c-MPL deficiency, but not CD41 blockade. (B) Quantitative scoring analysis of osteoblast layer number (mean 6 SEM) at baseline in WT and mpl2/2
mice (n5 5 mice each); in WTmice receiving TBI only (n5 19), or blockade of c-MPL (n5 10), CXCR4, or CD41 (n5 5 each); and inmpl2/2mice receiving TBI only (n5 19) or
TBI plus blockade of CXCR4 or CD41 (n 5 5 each). *P , .01 vs unirradiated group within same strain, 1P , .05 vs WT mice receiving TBI only in TBI-treated groups
(comparisons performed by 1-way ANOVA and Dunnett posttest analysis).
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(Figure 3A). Signiﬁcant increases were also seen post-TBI in 2
megakaryocyte survival factors: SDF-1 and TPO (Figure 3A).
Supporting the candidacy of PDGF-BB, BM PDGF-BB levels
at 48 hours post-TBI were decreased by 92% in mpl2/2 vs WT mice
(Figure 3B; P , .001). Although baseline PDGF-BB levels were
also decreased in mpl2/2 vs WT mice (supplemental Figure 2A),
the speciﬁc increase in BM PDGF-BB after TBI was also reduced
in mpl2/2 vs WT mice (2.7- vs 4.9-fold; P, .02). In contrast, c-MPL
blockade in WT mice produced only modest reductions in post-TBI
levels of PDGF-BB (P 5 .07), suggesting that decreased BM mega-
karyocytes, rather than the absence of c-MPL signaling, causes
decreased PDGF-BB production in mpl2/2 BM. Similar to its effects
on osteoblast proliferation, CD41 blockade in WT mice had no
impact on PDGF-BB levels. In contrast to PDGF-BB, post-TBI BM
levels of VEGF, IGF-1, and SDF-1 did not differ signiﬁcantly
among WT, mpl2/2, anti-CD41–treated WT, or anti-c-MPL–treated
WT mice, whereas post-TBI BM TPO levels were increased 1.8-fold
in untreated WT mice vs other groups (P , .01; Figure 3B).
PDGF receptor b (PDGFRb) is expressed at high levels by
endosteal osteoblasts both at baseline and 48 hours post-TBI
(supplemental Figure 2B-C). To determine whether megakaryocyte-
derived PDGF-BB mediates megakaryocyte effects on osteoblast
expansion, we used an in vitro coculture system13 with isolated primary
osteoblasts and puriﬁed ex vivo–expanded primary megakaryocytes
(Figure 3C). After 5 days, osteoblasts cocultured with megakaryocytes
demonstrated 2.2-fold increased growth relative to osteoblasts cultured
alone (P , .001); reciprocally, coculture with osteoblasts led to
enhanced growth and survival duration of the megakaryocyte
fraction (Figure 3D). Osteoblasts cocultured with megakaryocytes
produced signiﬁcantly more IGF-1, VEGF, and SDF-1 than did
cultures of osteoblasts alone, whereas megakaryocyte-derived
PDGF-BB levels decreased when megakaryocytes were cocultured
with osteoblasts, suggesting consumption of PDGF-BB by expand-
ing osteoblasts (Figure 3E; P, .001). When cultured across a 0.4-mm
transwell membrane, megakaryocytes still signiﬁcantly increased
osteoblast growth vs cultures of osteoblasts alone (P , .005)
(Figure 3F), indicating again that megakaryocyte-derived paracrine
factors drive osteoblast growth. Importantly, the addition of PDGF-
BB to osteoblast cultures recapitulated the enhancement of osteoblast
growth seen with megakaryocyte coculture (Figure 3G). Further-
more, treatment of megakaryocyte/osteoblast cocultures with imatinib,
a potent inhibitor of PDGFR signaling,27 completely abolished both
megakaryocyte-induced osteoblast expansion and osteoblast effects
on megakaryocyte survival in vitro (Figure 3D). By contrast, neither
c-MPL nor CD41 inhibition blocked growth of cocultured megakar-
yocytes and osteoblasts (Figure 3D), consistent with the failure of these
manipulations to inhibit BMPDGF-BB production in vivo (Figure 3B).
To determine whether PDGF-BB is also required for TBI-
induced endosteal osteoblast expansion in vivo, we treated mice pre-
and post-TBI with imatinib. Similar to inhibition seen in mpl2/2
mice, blockade of PDGFR signaling induced by imatinib resulted
in near-complete abrogation of endosteal osteoblast expansion post-
TBI, and as a consequence of either blocking niche expansion
or inhibiting megakaryocyte PDGFR signaling directly, post-TBI
imatinib treatment led to decreased megakaryocyte endosteal
migration (Figure 3H-I). We next treated both WT and mpl2/2
mice after TBI with recombinant PDGF-BB, ﬁnding that PDGF-BB
not only enhanced TBI-induced endosteal osteoblast expansion in
WT mice but also partially rescued the niche osteoblast expansion
deﬁcit in mpl2/2 mice (Figure 3J and supplemental Figure 2D).
Thus, PDGF-BB is a critical megakaryocyte-derived mediator of
niche osteoblast expansion after TBI.
Post-TBI megakaryocyte modulation of the endosteal niche
is required for efficient donor progenitor and
LT-HSC engraftment
As reported previously,24 baseline long-term (LT)-HSC were reduced
by 76% in mpl2/2 vs WT BM, although mpl2/2 BM compensates
for this deﬁcit, by producing relatively normal numbers of late
hematopoietic progenitors, leading to overall normal BM cellular-
ity at baseline (Figure 4A and supplemental Figure 3A-B). To
assess whether diminished post-TBI megakaryocyte-driven endos-
teal osteoblast expansion in mpl2/2 mice inﬂuences the efﬁciency
and speed of initial donor BM engraftment and hematopoietic
expansion, while avoiding confounding effects from decreased
HSC in mpl2/2 mice, we transplanted transgenic GFP1 BM20 with
normal c-MPL expression into irradiated (48-hour post-TBI) WT
or mpl2/2 primary (1°) recipients. Because CD41 is not expressed
on LT-HSC,28 and anti-CD41 treatment of donor BM did not alter
donor HSC engraftment in control studies (data not shown), we also
asked whether blockade of host megakaryocyte migration post-TBI
by anti-CD41 treatment alters donor GFP1 BM engraftment.
From 24 hours through 3 weeks post-1° transplantation
(Figure 4B-D), GFP1 BM engraftment and expansion were sig-
niﬁcantly reduced (P, .01) by CD41 blockade (33%-49% reduction),
c-MPL deﬁciency (40%-55%), or both (41%-65% reduction). HSC
and progenitor cells were not detectable by ﬂow cytometry using
the established c-Kit1lin2Sca-11 (KLS) immunophenotype within
the BM of primary recipients for the ﬁrst 3 days after primary
transplant (Figure 4E), even when SCA-11–selected BM was used
as the donor BM source (supplemental Figure 3C-D), possibly
because of either inadequate sensitivity of ﬂow cytometry–based
detection or temporary alteration of the surface immunophenotype
of stem/progenitor populations posttransplant. However, at
5 and 7 days posttransplant, recovery of KLS cells occurred
earlier and to a greater extent in WT vs anti-CD41–treated mpl2/2
primary recipients (Figure 4E).
Next, we asked whether CD41 blockade or c-MPL deﬁciency
inhibited the efﬁciency of initial engraftment and expansion
speciﬁcally of ST or LT-HSC engraftment. To address this question,
we conducted competitive secondary transplantation repopulation
assays,22 using GFP1 donor BM as the donor source for 1° trans-
plantation, and irradiated WT, mpl2/2, or anti-CD41–treated WT
mice as 1° recipients (Figure 5A). In these assays, secondary (2°)
BMT was performed at either 24 hours or 3 weeks after 1° BMT to
assess differences in homing/initial HSC engraftment only and com-
bined initial engraftment and expansion, respectively. Harvested 1°
recipient BM was transplanted at a 5% BME dose22 (one ﬁfth of all
BM collected from one 1° recipient), together with unirradiated WT
whole BM competitor cells into irradiated secondary (2°) recipient
WT mice. Thus, the percentages of GFP1 cells in 2° recipient pe-
ripheral blood lineages served as a read-out for relative HSC
engraftment efﬁciency mediated by the distinct 1° recipient group
niche microenvironments. When 2° BMT was performed 24 hours
after 1° BMT, GFP1 engraftment of RBC, platelet, total white blood
count (WBC), GR-11 myeloid, and B2201 lymphoid lineages at 3
weeks after 2° BMT, was decreased by 83%, 97%, 89%,.99%, and
68%, respectively (P , .02) in 2° recipients of mpl2/2 vs WT 1°
recipient BM (Figure 5B). The 1° recipient CD41 blockade also
signiﬁcantly reduced 2° recipient GFP1 RBC (67%) and platelet
(90%) reconstitution 3 weeks after 2° BMT. However, reconsti-
tution of 2° recipients receiving even WT 1° recipient BM declined
from 6 to 24 weeks after 2° BMT (supplemental Figure 4),
suggesting that when 2° BMT is performed 24 hours after
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Figure 3. Megakaryocytes drive osteoblast expansion through PDGF-BB expression. (A) BM levels of PDGF-BB, IGF-1, VEGF, SDF-1, and TPO by ELISA (mean 6
SD) at baseline and at 48 hours post-TBI in WT mice. *P , .001 vs baseline. (B) Levels of BM PDGF-BB, IGF-1, VEGF, SDF-1, and levels in WT vs mpl2/2 mice with or
without CD41 or c-MPL antibody blockade (n 5 5 per group) at 48 hours post-TBI. *P , .05 vs WT TBI-only group. (C) Representative dot plots showing purity of isolated, ex
vivo–expanded megakaryocytes (MEG) and primary osteoblasts (OB) before coculture (left), together with nonadherent (top right) MEG and adherent (bottom right) OB
fractions after 5 days of coculture. (D) Five-day growth/survival of MEG and OB cultured separately or in combination (OB1MEG), with or without imatinib (5 mm), anti-CD41
antibody, or anti-c-MPL antibody (n 5 3 each; mean 6 SD). *P , .01 vs OB cultured alone, 1P , .001 vs MEG cultured alone. (E) VEGF, IGF-1, SDF-1, and PDGF-BB
supernatant concentrations (mean 6 SD, n 5 3 each) from 5-day cultures of OB, MEG, or cocultured OB 1 MEG. *P , .001 vs OB or MEG alone, 1P , .001 vs OB alone
or OB 1 MEG. (F) OB growth in 2- and 5-day OB cultures in which either MEG or medium alone was added to cultures across a 0.4-mM transwell membrane (n 5 3 each).
*P , .002 vs OB cultured with medium alone. (G) Five-day cultures of OB cultured with media alone or with increasing concentrations (2-10 ng/mL) of recombinant PDGF-BB
(n 5 3 each). *P , .01 vs cultures without PDGF-BB. (H) H&E-stained sections (403) of BM at 48 hours post-TBI, demonstrating abrogation of OB expansion (arrowheads)
caused by imatinib (right) vs sham (left) treatment. (I) Quantitative analysis of average OB layers (left) and percentage of endosteal MEG (right) at 48 hours post-TBI in
imatinib vs sham-treated WT mice (n 5 5 mice per group). *P , .005 vs sham-treated mice. (J) 403 photomicrographs of H&E-stained metaphyseal BM sections at 48 hours
post-TBI in WT and mpl2/2 mice demonstrating that treatment with PDGF-BB enhances 48-hour post-TBI endosteal OB proliferation (black arrows) in both WT and mpl2/2 BM.
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1° BMT, most measureable 2° recipient GFP1 engraftment was the
result of ST-HSC and primitive progenitor cells, but not LT-HSC.
We then performed 2° BMT 3 weeks after 1° BMT to assess for
differences in both initial engraftment and early expansion of HSC
caused by the distinct niche environments in our 1° recipient groups.
Most 2° recipients of WT 1° recipient BM (57%) demonstrated
multilineage GFP1 reconstitution from 12 (Figure 5C) to 24 weeks
(Figure 5D) after 2° BMT. Strikingly, c-MPL deﬁciency and CD41
blockade in the 1° recipient host megakaryocyte/endosteal niche
produced >99% reduction in GFP1 myeloid (GR-11), RBC, and
platelet engraftment in 2° recipients at 12 weeks after 2° BMT
(Figure 5C; P , .001), with smaller albeit signiﬁcant reductions
Figure 4. Blockade of host megakaryocyte function post-TBI decreases BM engraftment and expansion in primary transplant recipients. (A) Baseline LT-HSC
(c-kit1Lin2SCA-11CD135lo), ST-HSC (c-kit1Lin2SCA-11CD1351CD341), common lymphoid progenitors (CLP, Lin2CD1271), and common myeloid progenitors (CMP,
c-kit1Lin2SCA-12CD341CD1272) in WT andmpl2/2 BM, expressed as the percentage of all live BM cells (mean6 SD, n 5 3 each). *P , .05 vs percentage in WT mice.
(B) Representative dot plot and histogram demonstrating method of determining percentages of live, GFP1 donor cells within irradiated recipient BM at 24 hours after
BMT, used with total BM cell counts to determine absolute donor GFP1 BM cells. (C) Absolute live BM GFP1 donor cells (individual mice and/or mean per group) shown
at 24 hours (left), 3 to 7 days (middle), and 3 weeks (right) post-BMT of 5 3 106 (24 hours to 7 days), or 2 3 105 (3 weeks) GFP1 whole BM cells into post-TBI primary
recipient WT or mpl2/2 mice 6 recipient treatment with anti-CD41 at the time of TBI (n 5 3-5 mice per group). *P , .05 vs WT recipients. (D) H&E-stained histologic
sections showing decreased BM cellularity in anti-CD41–treated mpl2/2 (bottom) vs WT (top) recipients of GFP1 donor BM at 3 weeks post-BMT. (E) Flow cytometry
dot plots of c-Kit vs SCA-1 expression on live GFP1Lin2 gated whole BM cells from H2K-GFP donor BM before transplant (used to establish the HSC/progenitor
c-Kit1lin2Sca-11 [KLS] gate), and from either WT (top, right) or anti-CD41–treated mpl2/2 (bottom, right) primary recipients (pooled BM from 2-4 mice per time point), at
3, 5, and 7 days post-BMT with GFP1 whole BM cells (3-5 3 106 cells per mouse). Rectangle in each plot represents KLS population with frequency expressed as
a percentage of live GFP1Lin2 cells and of total live cells (in parentheses).
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in lymphocyte engraftment (P , .05). These LT-HSC engraftment
deﬁcits remained signiﬁcant through 24 weeks after 2° BMT
(Figure 5D). We concluded that not only is TBI-induced niche
osteoblast expansion required for efﬁcient donor HSC engraftment,
but megakaryocyte migration to the niche is also critical as
CD41 blockade, which prevents megakaryocyte migration but
not niche osteoblast expansion, severely impedes donor HSC
engraftment.
Figure 5. LT-HSC engraftment after BMT is severely impaired by blockade of host megakaryocytes. (A) GFP1 donor engraftment in competitive secondary (2°)
transplant (BMT) assays in which GFP1 donor BM was transplanted (5 3 106 BM cells) into post-TBI WT, anti-CD41–treated WT, and mpl2/2 primary (1°) recipients. (B) In
the initial assay, BM was harvested 24 hours after 1° BMT and transplanted with 2 3 105 WT competitor BM cells into post-TBI WT 2° recipients. GFP1 peripheral RBC, platelet,
total WBC, myeloid (GR-11), and B-cell (B2201) engraftment at 3 weeks after 2° BMT is shown. *P , .05 vs 2° recipients receiving WT 1° recipient BM. (C) Separate competitive
transplant assay showing GFP1 peripheral RBC, platelet, total WBC, myeloid, B-cell, and T-cell (CD31) engraftment at 12 weeks after competitive 2° BMT with 105 WT competitor
BM cells, and either WT, WT1 aCD41, ormpl2/2 1° recipient BM, harvested 3 weeks after 1° recipient BMT with 23 105 GFP1 donor BM cells. *P, .05 vs 2° recipients receiving
WT 1° recipient cells. (D) Percentage of competitively transplanted 2° recipients receiving WT, WT 1 aCD41, or mpl2/2 1° recipients cells 3 weeks after 1° BMT demonstrating
.3% GFP1 cells in specified lineage from 3 to 24 weeks after 2° BMT. *P , .05 vs percentage of 2° recipients of anti-CD41–treated or mpl2/2 1° recipient BM.
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TPO treatment enhances TBI-induced niche osteoblast
expansion and engraftment after BMT
Having demonstrated that blockade of host megakaryocytes post-
TBI impedes HSC engraftment, we hypothesized that augmenta-
tion of megakaryocyte function through TPO administration might
enhance engraftment. Therefore, we administered TPO at low
(10-mg/kg) and high (50-mg/kg) doses for 7 days before BMT
using a schedule (Figure 6A), based on the half-life of TPO,29
designed to limit treatment effects to the recipient’s BM microen-
vironment pretransplant, thereby avoiding direct TPO effects on
c-MPL–expressing donor HSC. Indeed, TPO levels in plasma or
BM were not increased by the time of BMT in TPO- vs sham-
treated mice using this schedule (supplemental Figure 5B).
TPO administered in the absence of TBI increased total numbers
of BM megakaryocytes but did not induce signiﬁcant endosteal
osteoblast expansion (supplemental Figure 5A). Although low-
dose TPO had only marginal effects, high-dose TPO given before
TBI led to substantially increased endosteal megakaryocytes 48 hours
post-TBI (Figure 6B). The increased megakaryocytes correlated
with a 34% increase (P , .001) in osteoblast layer expansion at
48 hours post-TBI in high-dose TPO- vs sham-treated mice, with
additional qualitative increases in osteoblasts displaying cuboidal
(less ﬂattened) morphologic patterns (Figure 6C-D). This increased
endosteal osteoblast expansion was not associated with increased
BM SDF-1 or PDGF-BB expression in high-dose TPO-treated
mice (supplemental Figure 5C-D).
Primary transplant studies showed that high-dose TPO vs sham
treatment of recipients led to a ;40% increase in GFP1 donor BM
engraftment 24 hours post-BMT (Figure 6E; P , .05). To test
effects of TPO given before transplant on HSC engraftment, we
performed another competitive secondary transplantation assay,
selecting cell doses and timing between 1° and 2° transplants
(36 hours) similar to the experiment in Figure 5B, where few
2° recipients of WT 1° recipient BM maintained GFP1 LT-HSC
engraftment. At 6 weeks after 2° BMT (Figure 6F), high-dose
TPO treatment of 1° recipients before 1° BMT with GFP1 donor
BM led to increased mean percentages of 2° recipient GFP1 RBC
(3.9-fold; P, .001), myeloid Gr-11 cells (20-fold; P, .02), B2201
B cells (14-fold; P, .001), and CD31 T cells (10-fold; P, .02) vs
percentages in 2° recipients of sham-treated WT 1° recipient BM.
At 28 weeks after 2° BMT, combined multilineage (myeloid,
B cell, T cell) and progenitor (lineage-negative) GFP1 BM en-
graftment, indicative of LT-HSC engraftment, was seen in 7 of 15
(47%) 2° recipients of high- dose TPO-treated 1° recipient BM vs
only 1/14 (7%) 2° recipients of sham-treated 1° recipient BM
(Figure 6G-H; P , .05), indicating that high-dose TPO adminis-
tration pretransplant, with consequent enhanced megakaryocyte-
driven niche remodeling, improves LT-HSC engraftment.
Discussion
Our data indicate that host megakaryocytes are recruited to the
endosteal HSC niche after radioablative conditioning, where they
stimulate niche expansion, and facilitate engraftment of HSC after
transplantation. These conclusions are based on evidence that
(1) decreased numbers of megakaryocytes, suppression of TPO/c-
MPL signaling, and blockade of megakaryocyte-derived PDGF-
BB signaling all abrogated TBI-induced niche osteoblast expansion;
and (2) blockade of megakaryocyte recruitment to the niche
prevented efﬁcient engraftment of donor HSC after transplantation.
Critically, we also show that megakaryocyte function can be aug-
mented by TPO administered before transplantation, leading to
enhanced LT-HSC engraftment.
A fundamental question in our studies using mpl2/2 mice and
c-MPL blockade was whether TPO signaling through c-MPL on
megakaryocytes is a critical driver of post-TBI niche osteoblast
expansion. Figure 1 and 2 support essential contributions from
TPO/c-MPL signaling speciﬁcally on megakaryocytes but do not
rule out roles for quiescent HSC, which also express c-MPL.15
However, given that osteoblastic expansion occurs post-TBI, and
TBI rapidly induces host HSC death, it is unlikely that c-MPL on
HSC is a competing factor with megakaryocyte-derived signaling in
regulating TBI-induced osteoblast expansion.
Megakaryocytes are the major source of BM PDGF-BB30 at
baseline, and the profound deﬁcit in PDGF-BB levels post-TBI that
we found in mpl2/2 vs WT mice demonstrates that megakaryocytes
are the principal source of BM PDGF-BB post-TBI as well. TPO
signaling directly regulates megakaryocyte PDGF-BB expression31;
thus, reduced PDGF-BB expression in mpl2/2 mice post-TBI may
result from both decreased total megakaryocytes and absent TPO
signaling. Our data demonstrate that inhibiting or enhancing mega-
karyocyte function and PDGFR signaling, respectively, diminishes
and increases both in vitro osteoblast growth as well in vivo post-
TBI endosteal osteoblast expansion and suggest that megakaryocytes
and their production of PDGF-BB appear to be both necessary and
sufﬁcient to enable post-TBI endosteal niche expansion.
Our ﬁnding that mpl2/2 mice used as recipients in primary and
secondary transplant assays display decreased hematopoietic recon-
stitution and HSC engraftment and expansion reﬂects defective niche
function post-TBI caused by decreased megakaryocyte function,
and is not confounded by absent c-Mpl expression on HSC in
mpl2/2 mice. Since the donor BM cells used in these assays had
normal WT levels of c-MPL expression. It is possible that at longer
time points than we have studied after primary transplant,
recovery of donor BM cellularity in mpl2/2 primary recipients
would approach that seen in WT primary recipients, as niche
defects may be corrected with time by donor megakaryocytes with
normal c-MPL function. Thus, mpl2/2 mice may not be an ideal
model for studying effects of disrupting megakaryocyte/niche
interactions on long-term durability of HSC engraftment in primary
recipients. However, given that the primary goal of our transplant
studies was studying the initial speed and efﬁciency of HSC
engraftment short term (<3 weeks) in primary recipients, it is
unlikely that our results were signiﬁcantly inﬂuenced by donor
megakaryocyte effects on the niche.
An unexpected ﬁnding was that inhibition of the megakaryocyte-
speciﬁc aIIbb3 integrin via CD41 blockade severely impeded both
megakaryocyte migration to the endosteal niche and HSC en-
graftment after transplantation, but did not signiﬁcantly disrupt
megakaryocyte-driven niche osteoblast expansion. aIIbb3 integrin
regulates homeostatic megakaryocyte migration through its binding
to BM extracellular matrix components32; thus, abrogation of mega-
karyocyte migration post-TBI by anti-CD41 treatment is consistent
with integrin-mediated adhesion blockade. As discussed above,
anti-CD41 treatment of WT mice does not disrupt niche osteoblast
expansion likely because it does not decrease the total megakar-
yocyte number or PDGF-BB expression. Importantly, abrogation
of HSC engraftment by CD41 blockade suggests that the speciﬁc
presence of megakaryocytes at the niche could also be necessary
for maximal HSC engraftment efﬁciency. This hypothesis requires
future conﬁrmatory studies but is intriguing given the overlapping
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Figure 6. TPO administration before BMT enhances megakaryocyte-mediated expansion of niche osteoblasts and HSC engraftment. (A) Schedule of TPO
administration. (B) Immunostained (CD41) sections (203) comparing 48-hour post-TBI BM endosteal megakaryocytes (red arrowheads) after high-dose TPO (HDTPO,
50 mg/kg), low-dose TPO (LDTPO, 10 mg/kg), or sham treatment. (C) BM sections (203 top, 633 bottom) at 48 hours post-TBI showing increased endosteal osteoblast
expansion (black arrowheads) after HDTPO treatment vs LDTPO- or sham-treated mice. (D) Quantitative assessment of 48-hour post-TBI osteoblast layers (mean 6
SD) in sham-, LDTPO-, and HDTPO-treated WT mice (n $5 mice per group). *P , .005 vs sham-treated group. (E) Absolute BM GFP1 engraftment at 24 hours post-
BMT (5 3 106 cells) in post-TBI 1° recipients receiving sham, LDTPO, or HDTPO treatment (n5 5 per group). *P, .05 vs sham-treated group. (F) Secondary (2°) recipient GFP1
peripheral RBC, myeloid (GR-11), B-cell (B2201), and T-cell (CD31) engraftment at 6 weeks after 2° BMT with 2 3 105 WT competitor BM cells and either sham-,
LDTPO-, or HDTPO-treated primary (1°) recipient BM at 24 hours after 1° recipient BMT. *P , .02 vs 2° recipients of sham-treated 1° recipient BM. (G) Percentage of
2° recipients of sham, LDTPO, or HDTPO 1° recipient BM with GFP1 BM engraftment (.0.25% each) in myeloid, B-cell, T-cell, and Lin- BM populations at 28 weeks after
2° BMT. *P , .05 vs 2° recipients of sham-treated 1° recipient BM. (H) Representative dot plots of GFP vs Lin in BM at 28 weeks after 2° BMT in recipients of sham- vs
HDTPO-treated 1° recipient BM.
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functions of endosteal osteoblasts in both megakaryocyte and HSC
development and homeostasis.11,33
Many strategies have been devised to address problems of
inefﬁcient engraftment and graft failure in clinical HSCT, although
most efforts have focused on enhancing donor HSC function.34
TPO has been administered after transplantation in clinical trials,
but this strategy failed to either accelerate hematopoietic recovery
or improve outcome.35 By contrast, our TPO administration schedule,
which led to signiﬁcantly enhanced HSC engraftment, was chosen
speciﬁcally to (1) increase resident megakaryocyte numbers before
TBI; (2) increase TPO/c-MPL–dependent functions between TBI and
transplantation; and (3) avoid direct effects of TPO on c-MPL–
expressing donor HSC after transplantation. The precise cellular
and molecular pathways by which TPO administration and consequent
increased megakaryocyte function enhance HSC engraftment will
require considerable future investigation. Regardless, clinical strategies
using TPO mimetic treatment schedules that enhance megakaryocyte-
driven HSC niche functions in recipients before transplantation may
provide a novel approach to improving clinical transplantation
engraftment outcomes.
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